Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 382

1.

Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension.

Sharabi Y, Adler E, Shamis A, Nussinovitch N, Markovitz A, Grossman E.

Am J Hypertens. 2006 Jul;19(7):750-5.

PMID:
16814132
2.

Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?

Mahmud A, Mahgoub M, Hall M, Feely J.

Am J Hypertens. 2005 Dec;18(12 Pt 1):1631-5.

PMID:
16364838
3.

Effect of spironolactone on blood pressure in subjects with resistant hypertension.

Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators.

Hypertension. 2007 Apr;49(4):839-45. Epub 2007 Feb 19.

4.

The role of spironolactone in the treatment of patients with refractory hypertension.

Ouzan J, Pérault C, Lincoff AM, Carré E, Mertes M.

Am J Hypertens. 2002 Apr;15(4 Pt 1):333-9.

PMID:
11991219
5.

Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.

Gross E, Rothstein M, Dombek S, Juknis HI.

Am J Kidney Dis. 2005 Jul;46(1):94-101.

PMID:
15983962
6.

Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.

Bianchi S, Bigazzi R, Campese VM.

Am J Kidney Dis. 2005 Jul;46(1):45-51.

PMID:
15983956
7.

Medical management of aldosterone-producing adenomas.

Ghose RP, Hall PM, Bravo EL.

Ann Intern Med. 1999 Jul 20;131(2):105-8.

PMID:
10419425
8.

Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.

Dieterich HA, Wendt C, Saborowski F.

Fiziol Cheloveka. 2005 Nov-Dec;31(6):97-105. Review.

PMID:
16366159
9.
10.

Good blood pressure control on antihypertensives, not only response to spironolactone, predicts improved outcome after adrenalectomy for aldosteronoma.

Zarnegar R, Lee J, Brunaud L, Lindsay S, Kebebew E, Clark OH, Duh QY.

Surgery. 2007 Dec;142(6):921-9; discussion 921-9. Epub 2007 Nov 5.

PMID:
18063077
11.

Serum potassium levels predict blood pressure response to aldosterone antagonists in resistant hypertension.

Shlomai G, Sella T, Sharabi Y, Leibowitz A, Grossman E.

Hypertens Res. 2014 Dec;37(12):1037-41. doi: 10.1038/hr.2014.77. Epub 2014 Mar 27.

PMID:
24671013
12.

Low-dose spironolactone in the management of resistant hypertension: a surveillance study.

Lane DA, Shah S, Beevers DG.

J Hypertens. 2007 Apr;25(4):891-4.

PMID:
17351384
13.

Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure.

Cavallari LH, Groo VL, Viana MA, Dai Y, Patel SR, Stamos TD.

Pharmacotherapy. 2010 Jan;30(1):1-9. doi: 10.1592/phco.30.1.1.

PMID:
20030467
15.

Efficacy of spironolactone therapy in patients with true resistant hypertension.

de Souza F, Muxfeldt E, Fiszman R, Salles G.

Hypertension. 2010 Jan;55(1):147-52. doi: 10.1161/HYPERTENSIONAHA.109.140988. Epub 2009 Oct 26.

16.
17.

Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension.

Gaddam KK, Pratt-Ubunama MN, Calhoun DA.

Expert Rev Cardiovasc Ther. 2006 May;4(3):353-9. Review.

PMID:
16716096
19.

Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients.

Orea-Tejeda A, Colín-Ramírez E, Castillo-Martínez L, Asensio-Lafuente E, Corzo-León D, González-Toledo R, Rebollar-González V, Narváez-David R, Dorantes-García J.

Rev Invest Clin. 2007 Mar-Apr;59(2):103-7.

PMID:
17633796
20.

Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)--study protocol.

Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Husar R, Kocianova E, Taborsky M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011 Jun;155(2):143-8.

Items per page

Supplemental Content

Write to the Help Desk